<DOC>
	<DOC>NCT00307749</DOC>
	<brief_summary>The primary objectives of the study are to evaluate the efficacy and safety of three doses of MCC-257 in patients with mild to moderate diabetic polyneuropathy</brief_summary>
	<brief_title>Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy</brief_title>
	<detailed_description>The study will use a double-blind, randomized, placebo-controlled, fixed-dose, parallel-group design. Patients will be randomized equally to 1 of 4 treatment groups: MCC-257 20 mg, MCC-257 40 mg, MCC-257 80 mg, or placebo, given once daily for 24 weeks. The study will consist of 2 periods: 1) a screening period of up to 21 days prior to baseline, including a formal screening visit; and 2) a 24-week treatment period, during which patients will take the study treatment, and have various assessments performed during 4 visits.</detailed_description>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>The patient is male or female, 1870 years of age The patient has either type 1 or type 2 diabetes The patient has mild to moderate diabetic neuropathy The patient is free from other clinically significant illness or disease, as determined by medical history, physical examination, laboratory evaluations, and other safety tests Being treated with anticoagulants other than aspirin, such as warfarin, digoxin, Plavix BMI&gt;40 A significant disorder or a condition other than diabetes that can cause symptoms or physical conditions that mimic peripheral neuropathy or interfere with cognition Any proximal neuropathy, clinically evident nerve entrapment, or any focal trauma potentially affecting nerve function Women of childbearing potential who do not refrain from sexual activity or use adequate contraception Pregnant or lactating women An ALT or AST value &gt;2X upper limit of normal (ULN) Clinically significant cardiovascular disease within the last six (6) months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Neuropathy</keyword>
	<keyword>Nerve Conduction</keyword>
</DOC>